2017 No. 1117
Dangerous Drugs, England And Wales
Dangerous Drugs, Scotland
The Misuse of Drugs (Amendment) (No. 2) (England, Wales and Scotland) Regulations 2017
Made 16th November 2017
Laid before Parliament 20th November 2017
Coming into force 27th November 2017

The Secretary of State makes the following Regulations in exercise of the powers conferred by sections 7, 10, 22 and 31 of the Misuse of Drugs Act 1971.
1971 c. 38; section 22 was amended by section 177(1) of, and paragraph 12 of Schedule 4, to the Customs and Excise Management Act 1979 (c. 2); other amendments have been made to sections 7, 10 and 31 that are not relevant to these Regulations.
In accordance with section 31(3) of that Act the Secretary of State has consulted with the Advisory Council on the Misuse of Drugs.

1 Citation, commencement and extent
1 These Regulations may be cited as the Misuse of Drugs (Amendment) (No. 2) (England, Wales and Scotland) Regulations 2017 and come into force on the 27th November 2017.
2 These Regulations extend to England and Wales and Scotland.

Amendment of the Misuse of Drugs Regulations 2001
2 The Misuse of Drugs Regulations 2001are amended as follows.
S.I. 2001/3998. Relevant amending instruments are S.I. 2003/1432, S.I. 2005/1653, S.I. 2005/3372, S.I. 2006/986, S.I. 2007/2154, S.I. 2009/3136, S.I. 2010/1144, S.I. 2011/448, S.I. 2012/385, S.I. 2012/1311, S.I. 2013/176, S.I. 2013/625, S.I. 2014/1275, S.I. 2014/1377, S.I. 2014/3277, S.I. 2015/891, 2016/1125 and 2017/631.
3 In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27) after “Methylnaphthidate (HDMP-28)” insert—

“N-methyl-1-(thiophen-2-yl)propan-2-amine (methiopropamine or MPA)”

.
Ben Wallace Minister of State Home Office 16th November 2017

EXPLANATORY NOTE
(This note is not part of the Regulations)
These Regulations amend the Misuse of Drugs Regulations 2001 (“the Regulations”). The schedule to the Regulations in which a controlled drug is placed primarily affects the extent to which the drug can be lawfully imported, exported, produced, supplied or possessed and dictates the record keeping, labelling and destruction requirements in relation to that drug. The controlled drugs placed in Schedule 1 to the Regulations are those subject to the tightest controls.
Regulation 3 adds the drug methiopropamine or MPA and related materials to Schedule 1 to the Regulations.
A full impact assessment of the effect that this instrument will have on the costs of business and the voluntary sector is available and is published with the Explanatory Memorandum alongside the instrument on www.legislation.gov.uk.